12:00 AM
 | 
Oct 27, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AAV1-FS344: Phase I/IIa data

A dose-escalation Phase I/IIa trial in 6 patients with Becker muscular dystrophy showed that AAV1-FS344 given by direct bilateral intramuscular quadriceps injections improved 6MWT in 4 patients. In cohort 1 (n=3), 3*1011 vg/kg/leg AAV1-FS344 improved 6MWT by 58, 125 and...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >